To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Metastatic Triple Negative Breast Cancer
Interventions: DRUG: Olaparib Continuous (28-Day cycle) 300 mg BD.|DRUG: Ceralasertib 160 mg OD + olaparib continuous 300 mg BD (28-day cycle).|DRUG: Adavosertib 150 mg BD + olaparib 200 mg BD (21-day cycle).
Sponsor: AstraZeneca